2009
Narasimhan said that during the 2009 H1N1 pandemic the main challenge was scaling up manufacturing of the vaccine.
“scaling up for the H1N1 pandemic in 2009, the real challenge was the manufacturing scale up”
Topic
Vas Narasimhan is the CEO of Novartis, and the podcasts here cover his views on vaccines during the COVID-19 pandemic, drug pricing under the Inflation Reduction Act, and the future of medicine, speaking on Fortune's Leadership Next and STAT's The Readout Loud.
On Leadership Next, Narasimhan said vaccines have typically taken 10 to 12 years to develop, and that his own 18-month to two-year COVID-19 estimate was a guess. On The Readout Loud, he argued that the law's nine years before price controls on small-molecule drugs is too short. He also said he expects siRNA therapies, needed only every six months or year, to transform healthcare over time.
19 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2009
Narasimhan said that during the 2009 H1N1 pandemic the main challenge was scaling up manufacturing of the vaccine.
“scaling up for the H1N1 pandemic in 2009, the real challenge was the manufacturing scale up”
2009
Clifton Leaf said Vas Narasimhan led Novartis's effort to develop a vaccine during the 2009 H1N1 flu pandemic.
“Vas, who actually led Novartis' effort to develop a vaccine during the H1N1 flu pandemic of 2009”
2018
Narasimhan said the Novartis leadership program began about 18 months earlier and is based on adult development theory.
“this was actually a program we started, interestingly, 18 months ago, based on something called adult development theory”
2020
Vas Narasimhan said that no RNA or DNA vaccine had ever been approved for use.
“but we've never had an RNA or DNA vaccine approved.”
2020
Vas Narasimhan said he had put out an estimate of 18 months to two years for a COVID-19 vaccine, which he described as a guess.
“I put out a number of 18 months”
2020
Narasimhan cited reports that over 60 to 70% of physicians saw a dramatic drop in patient visits during the pandemic.
“you have over 60, 70 % of physicians reporting that they are seeing a dramatic reduction in patient visits.”
2020
Narasimhan cited a 30% drop in ER arrivals for heart attack and stroke and 80 to 90% lower cancer screening, the latter from one study.
“You see 30 % reductions in heart attack and stroke coming into the ER, epileptic seizures, reductions in cancer screening of 80 to 90%, I read in one study.”
2020
Narasimhan said roughly 20% to 40% of physician visits were being covered by telemedicine during the pandemic.
“I understand it's on the order of 20 % to 40 % of visits are now getting covered somehow by telemedicine.”
2020
Clifton Leaf said Novartis's total shareholder return was about 16% during Vas Narasimhan's first two years as CEO, versus about 6% for the S&P 500.
“Novartis' total return to shareholders has been about 16 % compared to about 6 % for the S &P 500 during that time.”
2020
Narasimhan co-chaired a CEO initiative with Bill Gates involving 17 global biopharmaceutical companies focused on equitable access to COVID-19 vaccines and drugs.
“co-lead the Gates CEO initiative with Bill Gates as the current co-chair with him. And in that discussion, so much of the focus amongst the 17 global biopharmaceutical companies”
2022
Vas Narasimhan argues that the Inflation Reduction Act's nine years before price controls for small-molecule drugs is too short to allow indication expansions, rare disease work and oncology and cardiovascular development.
“we believe that the nine years of protection before price controls take hold in the small molecule space is simply too short to really allow us to do the indication expansions”
2023
Novartis CEO Vas Narasimhan became chair of the board of PhRMA, the trade group representing the drug industry, in early 2023.
“last week there was a change at the top of pharma or the pharmaceutical research and manufacturers of america which is of course the trade group representing the drug industry”
2023
Narasimhan said that in many drug classes, rebates can be as much as 70% of a drug's list price.
“as you know, in many drug classes, that rebate can be as much as 70 % of the list price of the drug.”
2023
Narasimhan said small-molecule drugs, which face price setting after nine years under the Inflation Reduction Act, make up about 60% of the drugs the industry generates.
“that will have a big impact on what is really about 60% of the drugs this industry generates and many of those drugs targeting the elderly population.”
2023
Narasimhan said CAR-T cell therapy has struggled to move from B cell cancers into solid tumors because solid tumors are heterogeneous and reliable targets are hard to find.
“There was a huge amount of effort to move from B cell tumors into solid tumors. Solid tumors are so heterogeneous, it's been hard to find, I think, reliable targets”
Undated
Vas Narasimhan said vaccines have typically taken 10 to 12 years to develop for any single targeted pathogen.
“vaccines typically have taken us 10 to 12 years to develop for any one of the pathogens that we're targeting.”
Undated
Narasimhan said Novartis was among a group of companies that pioneered biotechnology, including antibody drugs and protein drugs.
“Later on, a group of companies, including us, pioneered biotechnology, the use of antibodies, larger drugs, proteins”
Undated
Narasimhan said there have probably been 12 or 13 pandemics during Novartis's roughly 250-year history.
“there's probably been about 12 pandemics, 13 pandemics in the history that Novartis has been around in the last 250 years.”
Undated
Narasimhan expects siRNA therapies that patients need only every six months or year, especially if directed beyond the liver, to transform healthcare over time.
“long-acting therapies that patients only need every six months or one year are going to transform healthcare over time.”
Episodes